探索治疗方法:从病理生理机制到新兴疗法
1Department of Dermatology, International St. Mary's Hospital, College of Medicine, Catholic Kwandong University, Incheon 22711, Republic of Korea.
International journal of molecular sciences
|May 25, 2024
概括
本综述探讨了的治疗方法,包括局部,全身和程序选项. 新兴疗法为个性化管理和改善患者治疗结果提供了新的希望.
科学领域:
- 皮肤病学 皮肤病学
- 医学科学 医学科学 医学科学
背景情况:
- 是一种普遍的皮肤疾病,影响青少年和年轻成年人.
- 它的复杂病原发生涉及遗传,荷尔蒙,微生物和炎症因素.
- 有效的管理需要解决各种类型的病变和导致因素.
研究的目的:
- 综合审查目前和新兴的的管理策略.
- 突出个性化治疗方法的重要性.
- 讨论创新疗法在治疗中的潜力.
主要方法:
- 对当前和新兴管理策略的文献综述.
- 对局部,系统,程序和饮食干预措施的分析.
- 检查新的治疗药物和方法.
主要成果:
- 已建立的治疗方法包括局部视网,氧化,抗生素和全身性药物.
- 像激光和化学皮肤这样的程序性疗法有助于减轻症状和痕.
- 新兴的选择包括生物制剂,菌体,益生菌和.
结论:
- 由于的复杂性,管理需要个性化策略.
- 目前的治疗方法为各种严重程度提供了显著的好处.
- 创新疗法显示出在治疗中改善患者治疗结果的希望.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
273
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
273
Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276
Asthma: Pathogenesis and Management
388
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
388
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Diabetes: Management and Pharmacotherapy
265
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
265


